Black docs warm to DTC ad benefits

Share this article:
A survey of members of the National Medical Association (NMA), an African-American physicians’ group, suggests a largely positive impression of DTC advertising on the part of black doctors but flags fears about ads overstating efficacy, presenting confusing risk/benefit information and pressuring them to prescribe advertised drugs.

The survey of 322 NMA members, supported by Pfizer, found perceptions of DTC much improved over 2001, when the organization last canvassed members on the topic.

Those seeing positive benefits to patients from DTC rose from 55% to 66% over those five years, while those reporting positive benefits to physicians from DTC jumped from 42% to 65%.
Specifically, 80% of respondents said DTC makes patients aware of treatment options, while 64% said ads alert them to problems earlier and 58% said consumer ads promote better patient education regarding disease states.

Nearly half of the doctors (45%) said ads are a beneficial educational tool for patients in underserved communities.

Respondents felt ads improve the patient-physician dialogue by triggering patients to seek their doctors’ opinions (80%), prompting thoughtful questions (73%), promoting better discussions in office visits (60%) and motivating patients to visit their doctors (49%).

On the downside, more than three-fourths of NMA members surveyed said ads make people think meds work better than they do (76%) and confuses people about the relative risks and benefits of drugs (76%), while two-thirds (65%) said ads cause patients to second-guess diagnoses and 54% said they feel pressured to prescribe particular drugs because of ads.

The NMA, which boasts 30,000 members, recommends more disease awareness advertising around chronic ailments that plague minority communities, along with more advertising in African-American media and greater cultural diversity and sensitivity in ads.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...